Amylin as a Future Obesity Treatment
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Obesity is defined as abnormal or excessive fat accumulation that contributes to detrimental health impacts. One-third of the population suffers from obesity, and it is important to consider obesity as a chronic disease requiring chronic treatment. Amylin is co-secreted with insulin from β pancreatic cells upon nutrient delivery to the small intestine as a satiety signal, acts upon sub-cortical homeostatic and hedonic brain regions, slows gastric emptying, and suppresses post-prandial glucagon responses to meals. Therefore, new pharmacological amylin analogues can be used as potential anti-obesity medications in individuals who are overweight or obese. In this narrative review, we analyse the efficacy, potency, and safety of amylin analogues. The synthetic amylin analogue pramlintide is an approved treatment for diabetes mellitus which promotes better glycaemic control and small but significant weight loss. AM833 (cagrilintide), an investigational novel long-acting acylated amylin analogue, acts as a non-selective amylin receptor. This calcitonin G protein-coupled receptor agonist can serve as an attractive novel treatment for obesity, resulting in reduction of food intake and significant weight loss in a dose-dependent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Amylin is co-secreted with insulin from pancreatic β-cells in response to food intake, delays gastric emptying, inhibits glucagon secretion, improves glycaemia, increases satiety, and reduces food intake without decreasing energy expenditure (appendix p 6), [146][147][148] with a mode of action that differs from GLP-1.149”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [148]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Amylin acts on amylin receptors in the brainstem to reduce food intake [83] and improves glucose metabolism by delaying gastric emptying and inhibiting glucagon secretion [84, 85].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“As WL with GLP-1 RA and amylin analogues results both from distinct and overlapping pathways, a combination of these entero-pancreatic hormones may induce a synergistic WL effect [84].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [84]
In the citing paper
“It slows down the gastric emptying and inhibits the glucagon secretion – both these actions improve glycemia [60].”
In the citing paper
“Amylin is a pancreatic hormone secreted by β-cells in response to food intake.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Obesity Stigma: Important Considerations for Public Health
Puhl, R. M., & Heuer, C. A. (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.159491 · Cited by 1,917
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Mechanisms underlying weight loss after bariatric surgery
Miras, A. D., & le Roux, C. W. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.119 · Cited by 344
Self-citationEnebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316 · cited 1×
“…104.7± 19.2 106.9± 22.1 108.1± 17.2 104.0± 17.8 43.0± 11.0 46.0± 12.0 45.0± 14.0 44.0± 14.0 44.0± 12.0 46.0± 13.0 47.0± 12.0 73 71 72 75 71 73 73 Yes Yes Yes Yes Yes Yes NA Enebo et al. (2021)14 20 Randomized, placebo controlled 0.16 mg cagrilintide+2.4 mg semaglutide 0.30 mg cagrilintide+2.4…”
InfluentialLau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01751-7 · Cited by 278 · cited 1×
“…14.3 103.2± 17.8 49.9± 9.0 51.0± 8.0 50 50 Yes NA Aronne et al. (2007)30 16 Double-blind, placebo controlled 240 µg tid Placebo 137 67 37.9± 5.7 37.6± 5.5 105.5± 18.4 104.9± 19.1 48.0± 10.0 19.0± 10.0 80 81 Yes NA Lau et al. (2021)15 26 Double-blind, placebo controlled 0.3 mg cagrilintide once…”
InfluentialSelf-citationAmylin Agonists: A Novel Approach in the Treatment of Diabetes
Schmitz, O., Brock, B., & Rungby, J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s233 · Cited by 239
Lutz, T., Mollet, A., Rushing, P., Riediger, T., & Scharrer, E. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801664 · Cited by 223
Cited by
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Amylin acts on amylin receptors in the brainstem to reduce food intake [83] and improves glucose metabolism by delaying gastric emptying and inhibiting glucagon secretion [84, 85].”
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
“129 It functions as a satiety signal, acting upon brain regions involved in both homeostatic and hedonic appetite regulation; it also slows the gastric emptying, and thereby suppresses post-prandial glucagon responses to meals.”
BackgroundMediators of Amylin Action in Metabolic Control
Boyle, C. N., Zheng, Y., & Lutz, T. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082207 · Cited by 67
“Studies of the exact mechanism of action of this and other long acting amylin analogs are ongoing [8,63,218,221,222,224,225] and at least some of the effects seem to be mediated by the necessary interaction with specific amylin receptor subtypes [218,225].”
BackgroundPharmacologic Treatment of Obesity in Reproductive Aged Women
Nuako, A. A., Tu, L., Reyes, K. J. C., Chhabria, S. M., & Stanford, F. C. (2023) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-023-00350-1 · Cited by 67
Melson, E., Miras, A. D., & Papamargaritis, D. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0144 · Cited by 46
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000513 · Cited by 46
“19 The interaction of these neurons, specifically the lateral parabrachial nucleus pathway, needs to be further elucidated in future studies.”
BackgroundNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Self-citationGlucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
“Cagrilintide, with six amino acid substitutions in human amylin and a dual carboxylic fatty acid chain similar to semaglutide attached to the first amino acid, lysine, exhibits an extended half-life, allowing for a once-weekly subcutaneous administration regimen [97,98].”
BackgroundGogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“It slows down the gastric emptying and inhibits the glucagon secretion – both these actions improve glycemia [60].”
BackgroundNutrient-Based Appetite Regulation
Moris, J. M., Heinold, C., Blades, A., & Koh, Y. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22031 · Cited by 36
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity
Volčanšek, Š., Koceva, A., Jensterle, M., Janež, A., & Muzurović, E. M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01733-8 · Cited by 35
“Amylin primarily binds to receptors in the AP, initiating signals that are relayed to the NTS and lateral parabra-chial nucleus (LPBN) [47, 64].”
InfluentialHyperglycemia-driven signaling bridges between diabetes and cancer
Ghareghomi, S., Arghavani, P., Mahdavi, M., Khatibi, A., García‐Jiménez, C., & Moosavi‐Movahedi, A. A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116450 · Cited by 32
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3
Carvas, A. O., Leuthardt, A. S., Kulka, P., Lommi, G., Hassan, S., Coester, B., Lundh, S. H., Pers, T. H., Secher, A. L., Raun, K., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105836 · Cited by 29
“26,27 The objective with cagrilintide was to create a long-acting amylin analogue that effectively reduces body weight, while minimising adverse effects such as nausea and vomiting.”
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
Nicze, M., Dec, A., Borówka, M., Krzyżak, D., Bołdys, A., Bułdak, Ł., & Okopień, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158202 · Cited by 33
Rubinić, I., Kurtov, M., & Likić, R. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1243 · Cited by 27
“184 Amylin receptors are composed of the calcitonin receptor (CTR), a G protein-coupled receptor, and one of three receptor activity-modifying proteins (RAMP1-3) that amplify the binding of amylin to CTR.”
BackgroundDutta, D., Nagendra, L., Harish, B., Sharma, M., Joshi, A. S., Hathur, B., & Kamrul-Hasan, A. B. M. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_45_24 · Cited by 23
“[5,6] .”
Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue
Munch, H. K., Just, R., Mathiesen, J. M., Eriksson, P.-O., Villadsen, J. S., Vestergaard, B., Deryabina, M. A., Demmer, O., Skarbaliene, J., Hamprecht, D. W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01185 · Cited by 15
Keov, P., Christopoulos, G., Hick, C. A., Glendorf, T., Ballarín-González, B., Wootten, D. L., & Sexton, P. M. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.123.000865 · Cited by 15
Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments
Nabi‐Afjadi, M., Ostadhadi, S., Liaghat, M., Pasupulla, A. P., Masoumi, S., Aziziyan, F., Zalpoor, H., Abkhooie, L., & Tarhriz, V. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116808 · Cited by 15
The role of amylin, a gut–brain axis hormone, in metabolic and neurological disorders
Muhammad, T., Pastore, S. F., Good, K., Yu, W. H., & Vincent, J. B. (2025) · FASEB BioAdvances · doi:10.1096/fba.2024-00151 · Cited by 14
“54–57 While no other IAPP-based drugs have been approved since then, several new analogs are showing promise as potential treatments for obesity and diabetes.”
The protective effect of amylin in type 2 diabetes: Yes or no
Alanazi, M., Al-Kuraishy, H. M., Albuhadily, A. K., Al-Gareeb, A. I., Abdelaziz, A. M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177593 · Cited by 10
Role of amylin in feeding and satiation
Lutz, T. A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110587 · Cited by 12
“Recent years have seen a dramatic rise in the development of amylin analogues for their potential use as anti-obesity drugs(Cao et al., 2024b; Dehestani et al., 2021; Enebo et al., 2021; Hay et al., 2015; Lutz, 2022; Muller et al., 2022).”
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity
Pati, B., Sendh, S., Sahu, B., Pani, S., Jena, N., & Bal, N. C. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00107e · Cited by 10
Sun, Y., Luo, Y., Xiang, C., Xie, C. H., Huang, W., Sun, Z., Jones, K. L., Horowitz, M., Rayner, C. K., Ma, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15626 · Cited by 9
“48 Although amylin was not measured in the current study due to the lack of a suitable commercial assay, β -cell function, assessed by C-peptide, was markedly impaired in the T2D cohort at baseline.”
Amylin and the amylin receptors in migraine: Is there another pathway to target?
Moreno‐Ajona, D., Gosalia, H., Hoffmann, J., & Goadsby, P. J. (2025) · Cephalalgia · doi:10.1177/03331024251340066 · Cited by 8
“Of note, the positive provocation study of amylin (37) would appear to be in contrast to amylin analogues being useful managing weight gain and obesity (61).”
Amylin analogs for the treatment of obesity without diabetes: present and future
Panou, T., Gouveri, E., Popovic, D. S., & Papanas, N. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2409403 · Cited by 5
“Cagrilintide is a long-acting molecule with a significant affinity for the calcitonin G protein-coupled receptor [7,10,27].”
InfluentialShah, H., Mali, S., Ranga, S., Jadhav, C., Rukadikar, A. R., Singh, A. K., & Shamnani, G. (2022) · PubMed · Cited by 19
Alqatari, S. G., Alwaheed, A., Hasan, M. A., Argan, R. A., Alabdullah, M. M., & Shubbar, M. D. A. (2025) · Medicina · doi:10.3390/medicina61071292 · Cited by 11
Clemen, R., Fuentes-Lemus, E., Bekeschus, S., & Davies, M. J. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102835 · Cited by 6
“These are major knowledge gaps in understanding the role of amylin, amylin fibrils and aggregates in the progression of T1D and T2D.”
BackgroundInfluentialTreating obesity to optimize women’s health outcomes
Rubino, D., & Schon, S. B. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002595 · Cited by 4
GLP-1 and amylin receptor multiagonism with amycretin for obesity management
Khoo, B. C. E., & Tan, T. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01250-4 · Cited by 5
Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden
Dugbartey, G. J., Alornyo, K. K., Dapaa-Addo, C. O., Kwashie, E. K., Harley, Y., & Asiedu, B. N. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102247 · Cited by 7
“This hormone is responsible for energy expenditure, satiety, blood glucose regulation due to delayed gastric emptying and decreasing pancreatic glucagon secretion [176].”
Hadid, S. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000940 · Cited by 3
Treatment of suboptimal initial response or recurrent weight gain after Roux-en-Y gastric bypass
Makaronidis, J., & Gerö, D. (2024) · British journal of surgery · doi:10.1093/bjs/znae081 · Cited by 2
Krizova, J., Trachta, P., Mráz, M., Brutvan, T., Hoskovec, D., Dytrych, P., Cinkajzlová, A., Pšenička, O., & Haluzík, M. (2025) · Physiological Research · doi:10.33549/physiolres.935559 · Cited by 3
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
“AMYRs are widely distributed in the CNS, including the hypothalamus and nuclei of the dorsal-vagal complex such as the area postrema and nucleus tractus solitarius [103].”
Rao, H., Kumar, S., Ali, S. M. E., Asif, H. M., Kumar, M., Kumar, L., & Raja, A. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01942-3 · Cited by 3
Influence of adipocytokines on the bronchopulmonary system in abdominal obesity
Khudiakova, A. D., & Ragino, Y. I. (2023) · PULMONOLOGIYA · doi:10.18093/0869-0189-2024-34-1-74-79 · Cited by 2
Innovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine
Romantsova, T. I. (2024) · Obesity and metabolism · doi:10.14341/omet13184 · Cited by 5
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 4
Future Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
Inhibition of Human Amylin Aggregation: In Silico and In Vitro Studies
Mizgalska, K., Al-Aani, U., Jaidah, Y. A., Panek, D., Châari, A., & Bajda, M. (2025) · ACS Omega · doi:10.1021/acsomega.5c02443 · Cited by 2
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
“1 형 당뇨병 치료제로 승인된 pram-lintide 와 개발 중인 cagrilintide 는 임상시험에서 의미 있는 체중 감소를 보였으며, 특히 GLP - 1 수용체 작용제와의 병용요법이 활발히 연구되고 있다[ 21 , 22 ].”
Bousch, C., Bérubé, F., Babych, M., Ongeri, S., & Bourgault, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062598 · Cited by 2
“The inherent aggregation propensity of IAPP is not only associated with the pathogenesis of T2D but also complicates the design and formulation of peptide derivatives for the treatment of metabolic disorders, such as diabetes and obesity [12–14].”
Amylin role in glucose homeostasis and β-cell function: a robust justification
Almasoudi, S. H., Al‐kuraishy, H. M., Al-Gareeb, A. I., Eliwa, D., & Batiha, G. E. (2026) · Minerva Endocrinology · doi:10.23736/s2724-6507.26.04508-2 · Cited by 1
Byun, S., Sotzen, M. R., Knappenberger, M. A., Olekanma, D., Bento, M. T., & Skibicka, K. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04011-8 · Cited by 1
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.09.003 · Cited by 1
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
Guo, J., Bachor, T. P., Takahashi, R., Steffek, M., Fitzgerald, G. A., Huffman, B. J., Braun, D., Han, S. J., Sandmann, T., Ha, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.06.680810 · Cited by 2
Choice of Therapy in Obese Type 2 Diabetes
Jyotsna, V., & Deshmukh, S. (2022) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_2_22
New Perspectıves on Obesıty Related Novel Peptıdes
Koç, S., SARIYILDIZ, L., & Menevşe, E. (2023) · Ahi Evran Medical Journal · doi:10.46332/aemj.1215675 · Cited by 1
Mawgod, M. M. A. E., Mohammad, H., Abdulsattar, Z. A., Abdulrehman, A., Almaradhi, F. A., Alenzi, Y. M., Alanazi, A. M., & Alanazi, A. A. (2024) · Cureus · doi:10.7759/cureus.63191 · Cited by 1
Current Approach of Diabetes Mellitus in Obese Patients
Karaburgu, S. (2023) · doi:10.69860/nobel.9786053359111.8
Farmaci innovativi per il trattamento dell’obesità
Masi, D., Tuccinardi, D., & Watanabe, M. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01535-3 · Cited by 1
“Il meccanismo d’azione degli agonisti del GLP-1 si sovrap-pone in parte a quello degli analoghi dell’amilina e in parte è diverso, tale che una combinazione dei due analoghi ormonali può indurre un effetto sinergico di perdita di pe-so [13].”
Updates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004 · Cited by 1
Urbańska, K., Popiela, D., Stojak, Ł., Kwiatkowski, F., Grego, K., Grego, M., Baczewski, M., & Czyż, W. (2025) · Quality in Sport · doi:10.12775/qs.2025.37.57002
Anti-Obesity Agents on the Horizon
Kim, S. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.1.2
HbA1c reduction strategies: An overview of pharmacological interventions
Upadhye, K. S., Patidar, H., Bamnia, N., & Yadav, N. K. (2025) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_72_24 · Cited by 2
Pediatric Obesity Pharmacotherapy
Speakman, A., Ali-Geiger, F., & Mouzaki, M. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.05.001
Molecular and cellular targets in the management of metabolic diseases and disorders: An overview
Cariño‐Cortés, R., Isabel, S.-C. M., Antonio, E.-D. J., Luis, J.-S., Fernández‐Martínez, E., & Fernanda, V.-C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00004-4
Shahriar, M. F., Kabir, J., & Kong, Y. (2026) · Molecular Diversity · doi:10.1007/s11030-025-11455-5
“However, they still have adverse effects, including an ele - vated risk of hypoglycemia, nausea, vomiting, and reduced appetite [66, 68].”
Akhmedova, Z. G. A., & Kagramanova, D. I. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.1.2026.1672
“Rewiring the hypothalamus: emerging neuroendocrine and neurotechnological approaches to obesity”
Tiwari, G., Mundada, A. B., Mundada, P. A., Maheshwari, R. O. P. N., Singh, S., Kumar, R., Chellammal, H. S. J., & Sharma, P. (2026) · Biological Rhythm Research · doi:10.1080/09291016.2026.2635609 · Cited by 8
“Adiponectin has been found to be inversely related to obesity and the metabolic syndrome and thus reducing it may have therapeutic benefits (Dehestani et al. 2021; Kim et al. 2023).”
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“1) [87].”
Next-generation anti-obesity drugs: Mechanisms, molecules, and momentum
Mukheja, Y., Kondepudi, K. K., Chopra, K., & Bishnoi, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100701 · Cited by 1
Khan, B. W., Agha, S. A., Qamar, I., Khattak, M. H., Rehman, A., Qazi, T. I., Siddiqui, S. A., Zeeshan, N., Khan, U. Z., Bibi, H., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05809-5
Serum amylin levels in patients with multiple sclerosis: A cross-sectional case-control study
ÇINKIR, U., Bir, L. S., Tekin, S., Karagülmez, A. M., Avcı, E., & Şenol, H. (2026) · Medicine · doi:10.1097/md.0000000000050425
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.013
Retracted
Metadata
- Authors
- Dehestani, B., Stratford, N. R., & Roux, C. W. L.
- Affiliations
- University College Dublin (IE)
- Corresponding author
- Dehestani, Babak
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2021-12-30
- Volume
- 30
- Issue
- 4
- Pages
- 320-325
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC8735818
- OpenAlex
- W4200574551
- Cited by
- 72
- References
- 38
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 16 · 2023: 12 · 2022: 5
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- amylin, amylin analogues, obesity treatment, pramlintide, cagrilintide, amylin receptor, satiety, gastric emptying, weight loss, dietary intake, anti-obesity drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.